<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412020000300006</article-id>
<article-id pub-id-type="doi">10.24245/gom.v88i3.3598</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Metformina: interacciones moleculares, celulares y su repercusión en la Obstetricia. Revisión bibliográfica]]></article-title>
<article-title xml:lang="en"><![CDATA[Metformin: Cellular and molecular interactions and its&#8217; impact in obstetrics. Literature review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ayala-Yáñez]]></surname>
<given-names><![CDATA[Rodrigo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Ruíz]]></surname>
<given-names><![CDATA[Mario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alonso-de Mendieta]]></surname>
<given-names><![CDATA[Maitane]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cassis-Bendeck]]></surname>
<given-names><![CDATA[Debborah Marie]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Frade-Flores]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Médico ABC  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Asociación Hispano Mexicana  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>88</volume>
<numero>3</numero>
<fpage>161</fpage>
<lpage>175</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412020000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412020000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412020000300006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO:  Identificar los mecanismos celulares más reconocidos de la metformina y su relación con patologías en Obstetricia y determinar las moléculas y vías involucradas con potencial terapéutico.  METODOLOGÍA:  Estudio retrospectivo efectuado con base en la búsqueda de artículos registrados en Pubmed y Cochrane publicados en inglés entre los años 2000 a 2019 que contuvieran las palabras clave (MeSH): &#8220;Metformin&#8221;; &#8220;Celular mechanisms&#8221;; &#8220;AMPK&#8221;; &#8220;LKB1&#8221;; &#8220;Gestational diabetes&#8221;, &#8220;Abortion&#8221; y &#8220;Preeclampsia&#8221;.  RESULTADOS:  Se encontraron 1750 artículos que contenían las palabras clave de búsqueda; al final solo se analizaron 57. En estos se concluye que la intervención con este fármaco inhibe el complejo I de la cadena respiratoria mitocondrial, con repercusión en varios procesos celulares. La diabetes gestacional, el aborto y la preeclampsia se consideraron por su incidencia y relevancia obstétrica, y por la indicación de la metformina en su tratamiento. Se identificaron los mecanismos involucrados en el efecto colateral gastrointestinal y la asociación con los mecanismos celulares influidos por la metformina. En los padecimientos obstétricos se identificaron los procesos metabólicos para tratamiento común, la diabetes gestacional fue la más identificada por la experiencia en diabetes mellitus.  CONCLUSIONES:  Si bien la metformina tiene una indicación clara en pacientes con diabetes gestacional, los resultados son insuficientes para aborto; en preeclampsia los mecanismos intervenidos pueden tener mayor potencial terapéutico y preventivo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE:  Identify the most recognized cellular mechanisms and their relations to obstetric pathology, determining molecular pathways for potential therapeutic use.  METHODOLOGY:  After a bibliographical search done in Pubmed and Cochrane database of MeSH terms: &#8220;metformin&#8221;, &#8220;cellular mechanisms&#8221;, &#8220;AMPK&#8221;, &#8220;LKB1&#8221;, &#8220;gestational diabetes&#8221;, &#8220;abortion&#8221;, &#8220;preeclampsia&#8221;, in the periods comprehending 2000 through 2019, a total of 49 references were selected, on the basis of the criteria established by the objective of this review.  RESULTS:  With 49 selected references, we found that metformin regulates adenosine monophosphate protein kinase (AMPK) and LKB1, both who which participate in metabolic mechanisms, activating second messengers who stimulate or inhibit processes like gluconeogenesis, steroid and protein synthesis and cellular growth. This drug actually acts by inhibiting complex I of the mitochondrial respiration process, impacting various cell functions. Gestational diabetes, abortion and preeclampsia are three obstetric pathologies selected due to their incidence and relevance, as well as the fact that metformin is being used for their treatment. We also identified the mechanisms for gastrointestinal symptoms where OCT-1, PMAT and 5-HT are involved and may be therapeutic targets. The association of cell mechanisms influenced by metformin are part of various metabolic pathways, being the ones in gestational diabetes the most, well known due to experience with diabetes mellitus.  CONCLUSIONS:  Although metformin has a clear role in gestational diabetes, results are insufficient to identify its&#8217; role in abortion. As for preeclampsia, the mechanisms identified have a greater preventive and therapeutic potential.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Metformina]]></kwd>
<kwd lng="es"><![CDATA[mecanismos celulares]]></kwd>
<kwd lng="es"><![CDATA[AMPK]]></kwd>
<kwd lng="es"><![CDATA[LKB1]]></kwd>
<kwd lng="es"><![CDATA[diabetes gestacional]]></kwd>
<kwd lng="es"><![CDATA[preeclampsia]]></kwd>
<kwd lng="es"><![CDATA[aborto]]></kwd>
<kwd lng="en"><![CDATA[Metformin]]></kwd>
<kwd lng="en"><![CDATA[Cellular mechanisms]]></kwd>
<kwd lng="en"><![CDATA[AMPK]]></kwd>
<kwd lng="en"><![CDATA[LKB1]]></kwd>
<kwd lng="en"><![CDATA[Gestational Diabetes]]></kwd>
<kwd lng="en"><![CDATA[Preeclampsia]]></kwd>
<kwd lng="en"><![CDATA[Abortion]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin: historical overview]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2017</year>
<volume>60</volume>
<page-range>1566-76</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hesse]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Taubmann]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Die Wirkung des Biguanids und seiner Derivate auf den Zuckerstoffwechsel]]></article-title>
<source><![CDATA[Arch Exp Path Pharmacol]]></source>
<year>1929</year>
<volume>142</volume>
<page-range>290-308</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasik]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes and the biguanides: the mystery of each. Glucophage: serving diabetology for 40 years]]></source>
<year>1997</year>
<page-range>79</page-range><publisher-loc><![CDATA[Groupe Lipha, Lyon ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[WHO model list of essential medicines]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maida]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin regulates de incretin receptor axis via la pathway dependent on peroxisome proliferator-activated receptor-alpha in mice]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2011</year>
<volume>54</volume>
<page-range>339-49</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of genetic variation in the organic cation transporter 1 (OCT-1) on metformin action]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2007</year>
<volume>117</volume>
<page-range>1422-31</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad de la metformina en pacientes con diabetes tipo II según variantes del gen SLC22A1]]></article-title>
<source><![CDATA[Acta Bioquím Clín Latinoam]]></source>
<year>2014</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>229-35</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of AMP-activated protein kinase in mechanism of metformin action]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2001</year>
<volume>108</volume>
<page-range>1167-74</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structure of mammalian AMPK and its regulation by ADP]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2011</year>
<volume>472</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>30-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viollet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cellular and molecular mechanisms of metformin: an overview]]></article-title>
<source><![CDATA[Clin Sci (Lond)]]></source>
<year>2012</year>
<numero>122</numero>
<issue>122</issue>
<page-range>253-70</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stephenne]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2011</year>
<volume>54</volume>
<page-range>3101-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McInnes]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulation of LKB1 expression by sex hormones in adipocytes]]></article-title>
<source><![CDATA[Int J Obes]]></source>
<year>2011</year>
<volume>36</volume>
<page-range>982-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin]]></article-title>
<source><![CDATA[Science]]></source>
<year>2005</year>
<volume>310</volume>
<page-range>1642-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2009</year>
<volume>137</volume>
<page-range>635-46</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2008</year>
<volume>57</volume>
<page-range>306-14</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takashima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2010</year>
<volume>59</volume>
<page-range>1608-15</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foretz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin inhibits hepatic gluconeogenesis in mice independently for the LKB1/AMPK pathway via a decrease in hepatic energy state]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2010</year>
<volume>120</volume>
<page-range>2355-69</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AMP activated protein kinase is required for the lipid lowering effect of metformin in insulin resistant human HepG2 cells]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>2004</year>
<volume>279</volume>
<page-range>47898-905</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dujic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes a GoDARTS study]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2015</year>
<volume>64</volume>
<page-range>1786-93</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2014</year>
<volume>2</volume>
<page-range>481-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pharmacokinetics of metformin]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2011</year>
<volume>50</volume>
<page-range>81-98</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2015</year>
<volume>352</volume>
<page-range>519-28</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cubeddu]]></surname>
<given-names><![CDATA[LX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors]]></article-title>
<source><![CDATA[Naunyn Schmiedebergs Arch Pharmacol]]></source>
<year>2000</year>
<volume>361</volume>
<page-range>85-91</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCreight]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin and the gastrointestinal tract]]></article-title>
<source><![CDATA[Diabetología]]></source>
<year>2016</year>
<volume>59</volume>
<page-range>426-35</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin and the intestine]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2008</year>
<volume>51</volume>
<page-range>1552-3</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2001</year>
<volume>24</volume>
<page-range>489-94</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An increase in the Akkermansia spp population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2014</year>
<volume>63</volume>
<page-range>727-35</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of metformin on metabolic improvement and gut microbiota]]></article-title>
<source><![CDATA[Appl Environ Microbiol]]></source>
<year>2014</year>
<volume>80</volume>
<page-range>35-5943</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dirar]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Doupis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gestational diabetes from A to Z]]></article-title>
<source><![CDATA[World J Diabetes]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>489-506</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dainelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening and management of gestational diabetes in Mexico: Results from a survey of multilocation, multi-health care institution practitioners]]></article-title>
<source><![CDATA[Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy]]></source>
<year>2018</year>
<volume>11</volume>
<page-range>105-16</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="book">
<source><![CDATA[Diagnóstico y tratamiento de la diabetes en el embarazo. Guía de Práctica Clínica]]></source>
<year>2016</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glueck]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: Prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy]]></article-title>
<source><![CDATA[Hum Reprod]]></source>
<year>2004</year>
<volume>19</volume>
<page-range>510-21</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AMP-activated protein kinase mediates effects of oxidative stress on embryo gene expression in a mouse model of diabetic embryopathy]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2012</year>
<volume>55</volume>
<page-range>245-54</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H-Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lack of metformin effect on mouse embryo AMPK activity: Implications for metformin treatment during pregnancy Diabetes]]></article-title>
<source><![CDATA[Metab Res Rev]]></source>
<year>2014</year>
<volume>30</volume>
<page-range>23-30</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jastrow]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of birth weight on adverse obstetric outcomes in vaginal birth after cesarean delivery]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2010</year>
<volume>115</volume>
<page-range>338-43</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased risk of cardiovascular disease in young women following gestational diabetes mellitus]]></article-title>
<source><![CDATA[Diab Care]]></source>
<year>2008</year>
<volume>31</volume>
<page-range>1668-9</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerrero-Romero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Birthweight, family history of diabetes, and metabolic syndrome in children and adolescents]]></article-title>
<source><![CDATA[J of Pediatric]]></source>
<year>2010</year>
<volume>156</volume>
<page-range>719-23</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiswick]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of metformin on maternal and fetal outcomes in obese pregnant women. EMPOWaR: A randomized, double blind, placebo controlled trial]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2015</year>
<volume>3</volume>
<page-range>778-86</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanford]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin vs Placebo in Obese Pregnant Women without Diabetes Mellitus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>374</volume>
<page-range>434-43</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Balani]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shehata]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin in Pregnancy: Mechanisms and Clinical Applications]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1954</numero>
<issue>1954</issue>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alqudah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of preeclampsia in women taking metformin: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Diabet Med]]></source>
<year>2018</year>
<volume>35</volume>
<page-range>160-72</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowan]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin versus insulin for the treatment of gestational diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>358</volume>
<page-range>2003-15</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Butalia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short and long-term outcomes of metformin compared with insulin alone in pregnancy: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Diabet Med]]></source>
<year>2017</year>
<volume>34</volume>
<page-range>27-36</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin in Pregnancy: Mechanisms and clinical applications]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1954</numero>
<issue>1954</issue>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety considerations with pharmacological treatment of gestational diabetes mellitus]]></article-title>
<source><![CDATA[Drug Safety]]></source>
<year>2015</year>
<volume>38</volume>
<page-range>65-78</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowan]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin in gestational diabetes The offspring follow-up (MiG TOFU): Body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res]]></article-title>
<source><![CDATA[Care]]></source>
<year>2018</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes (Review)]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2018</year>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glueck]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2001</year>
<volume>75</volume>
<page-range>46-52</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schermeck]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy outcome after first-trimester exposure to metformin: a prospective cohort study]]></article-title>
<source><![CDATA[Reprod Toxicol]]></source>
<year>2018</year>
<volume>81</volume>
<page-range>79-83</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osungbade]]></surname>
<given-names><![CDATA[KO]]></given-names>
</name>
<name>
<surname><![CDATA[Ige]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Public health perspectives of preeclampsia in developing countries: implication for health system strengthening]]></article-title>
<source><![CDATA[J Pregnancy]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abalos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global and regional estimates of preeclampsia and eclampsia: a systematic review]]></article-title>
<source><![CDATA[European Journal of Obstetrics &amp; Gynecology and Reproductive Biology]]></source>
<year>2013</year>
<volume>170</volume>
<numero>1-7</numero>
<issue>1-7</issue>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brownfoot]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin as a prevention and treatment for preeclampsia: Effects on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin secretion, and endothelial dysfunction]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2016</year>
<volume>214</volume>
</nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cluver]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A doble blind, randomised, placebo controlled trial to evaluate the efficacy of metformin to treat preterm preeclampsia (P12 Trial): study protocol]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Ambrosio]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin reduces maternal weight gain in obese pregnant women: a systematic review and meta-analysis of two randomized controlled trials]]></article-title>
<source><![CDATA[Diabetes Metab Res Rev]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nascimento]]></surname>
<given-names><![CDATA[IBD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of preeclampsia results after use of metformin in gestation systematic review and meta-analysis]]></article-title>
<source><![CDATA[Rev Bras Ginecol Obstet]]></source>
<year>2018</year>
<volume>40</volume>
<page-range>713-21</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pushpakom]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug repurposing: progress, challenges and recommendations]]></article-title>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2019</year>
<volume>18</volume>
<page-range>41-58</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
